Abbott Laboratories
ABT----
Q2 FY2026 EarningsQ2 FY26 revenue reached $12.59B, up 13.0% YoY on a reported basis and 4.8% on a comparable basis. Reported Diagnostics sales surged 42.3% YoY following the Exact Sciences acquisition, while Medical Devices grew 9.0%. GAAP diluted EPS was $0.53, impacted by acquisition-related charges and tax adjustments, while Adjusted diluted EPS rose 4.0% YoY to $1.31. Management raised full-year 2026 Adjusted EPS guidance to $5.45-$5.60.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Abbott Laboratories(ABT) predict that the Revenue is 12.59 B (+13.02%), Beat estimate;the EBIT is 2.843 B (+11.45%), Beat estimate;the EPS is 0.53 (-47.52%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
12.59B13.02%
12.52B12.34%
+0.08B0.68%
EBITExceed expectations
2.84B11.45%
2.79B9.56%
+0.05B1.89%
EPSMiss expectations
0.5347.52%
0.94926.02%
-0.419241.50%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf